A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus (NCT06015737)
A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus Who Are Refractory and/or Intolerant to Antimalarial Therapy.
🩺 Plain-English Summary (8th-Grade Level)
This study aims to evaluate the efficacy and safety of subcutaneous (SC) anifrolumab versus placebo in adult participants with chronic and/or subacute cutaneous lupus erythematosus (CLE).
Who can join: Review the eligibility criteria below.
Location: Research Site — Phoenix, Arizona
Age range: 18 Years to 70 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (188 Sites)
Showing the first 25 of 188 sites.
- Research Site — Phoenix, Arizona
- Research Site — Covina, California
- Research Site — La Jolla, California
- Research Site — Los Angeles, California
- Research Site — Los Angeles, California
- Research Site — Orange, California
- Research Site — San Francisco, California
- Research Site — Aurora, Colorado
- Research Site — New Haven, Connecticut
- Research Site — Washington D.C., District of Columbia
- Research Site — Fort Lauderdale, Florida
- Research Site — Miami, Florida
- Research Site — Plantation, Florida
- Research Site — Chicago, Illinois
- Research Site — Chicago, Illinois
- Research Site — Indianapolis, Indiana
- Research Site — Baltimore, Maryland
- Research Site — Boston, Massachusetts
- Research Site — Boston, Massachusetts
- Research Site — Ann Arbor, Michigan
- Research Site — Bloomfield Hills, Michigan
- Research Site — Rochester, Minnesota
- Research Site — Omaha, Nebraska
- Research Site — New York, New York
- Research Site — Rochester, New York
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Cutaneous Lupus Erythematosus clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.